GT Metabolic Solutions Secures Series C Investment from J.P. Morgan Life Sciences Private Capital to Accelerate Global Expansion
GT Metabolic™ Solutions, Inc., a medical technology company developing innovative surgical devices designed to improve gastrointestinal (GI) procedures, has announced a Series C growth investment from J.P. Morgan Life Sciences Private Capital. The investment will support the company’s ongoing global commercial launch, accelerate product development, expand surgeon training programs, and facilitate the introduction of its magnetic anastomosis technology into additional surgical and therapeutic applications.
The financing represents an important milestone for GT Metabolic as it advances its mission to improve surgical outcomes through a novel approach to creating gastrointestinal connections. The company plans to use the proceeds to expand its commercial activities across international markets and pursue new clinical applications, with endoscopic and colorectal surgery identified as key areas for further development. Additional indications are expected to follow as the company continues to broaden the potential use of its technology.
GT Metabolic has established a position in the medical device sector through its development of linear magnetic anastomosis technology. The company was the first to receive U.S. Food and Drug Administration (FDA) De Novo authorization and 510(k) clearance for the use of magnetic technology to create compression anastomoses. These connections join two tubular structures in the body, such as sections of the intestine, and are essential to numerous gastrointestinal surgical procedures.
The new investment is expected to provide GT Metabolic with the financial resources needed to advance its commercialization strategy, strengthen relationships with surgeons and healthcare providers, and expand access to its products in markets where the technology has received the necessary regulatory authorizations.
Advancing Magnetic Anastomosis Technology
GT Metabolic’s technology is designed to offer an alternative to conventional methods of creating gastrointestinal anastomoses. Standard surgical techniques commonly rely on sutures or staples to join two sections of tissue following the removal of diseased or damaged portions of the gastrointestinal tract or during other reconstructive procedures.
Although these methods are widely used, complications associated with anastomotic healing remain a significant concern for surgeons. Leaks and bleeding can lead to serious clinical consequences, including infection, sepsis, hospital readmission, additional interventions, and, in severe cases, death.
GT Metabolic’s linear magnetic anastomosis system uses magnetic compression to bring tissue surfaces together and facilitate the formation of a connection. The approach is designed to create an anastomosis without the need for conventional sutures or staples and without leaving permanent foreign material at the connection site.
According to the company, the system offers an incisionless, sutureless, staple-free, and reversible technique for creating gastrointestinal compression anastomoses. By using magnetic forces to bring tissue into contact, the technology aims to support the body’s natural healing processes while preserving the underlying biological characteristics of the tissue.
A key differentiator is the system’s design, which aims to produce fully patent anastomoses without leaving foreign material that could interfere with healing. Maintaining an open, functional connection is critical to the success of gastrointestinal procedures because the newly created passage must allow the normal movement of intestinal contents.
The company believes that its technology has the potential to address persistent challenges associated with anastomotic construction. By offering an alternative to conventional joining techniques, the system could provide surgeons with another option for performing complex gastrointestinal procedures while seeking to improve the reliability of tissue connections.
The technology is also designed to be compatible with different surgical access methods. Surgeons may use the system in procedures performed through endoscopic, robotic, or laparoscopic approaches, depending on the specific procedure and clinical requirements. This flexibility could support broader adoption across surgical settings as the company expands the range of procedures for which its products are authorized and available.
Addressing Complications in Gastrointestinal Surgery
Anastomotic complications remain an important issue in gastrointestinal surgery, where the successful joining of tissues is essential for recovery and long-term outcomes.
GT Metabolic estimates that up to 18% of gastrointestinal anastomotic procedures result in potentially life-threatening complications, including leaks and bleeding. Such complications can require emergency treatment, prolong hospitalization, and increase the burden on patients, healthcare professionals, and healthcare systems.
Anastomotic leakage occurs when the connection between two sections of tissue fails to seal adequately, allowing intestinal contents to escape into surrounding areas. This can trigger serious infections and inflammatory responses. In severe cases, patients may develop sepsis, a life-threatening condition caused by the body’s extreme response to infection.
Bleeding is another complication that can require additional monitoring or intervention. Depending on its severity, postoperative bleeding may contribute to prolonged recovery, additional procedures, or hospital readmission.
These risks have driven continued efforts to develop surgical technologies that improve the formation and healing of tissue connections. GT Metabolic is positioning its magnetic compression system as a potential advancement in this area, with the goal of creating consistent, functional anastomoses while reducing reliance on traditional mechanical joining methods.
The company’s approach is based on using magnetic compression to bring tissue together and support the formation of a connection through the body’s healing mechanisms. While the technology is intended to address longstanding surgical challenges, its clinical performance and potential benefits must be evaluated in the context of the applicable procedures, patient populations, and available clinical evidence.
By expanding its commercial presence and investing in further product development, GT Metabolic aims to make its technology accessible to a broader group of surgeons and patients.
J.P. Morgan Highlights the Technology’s Potential
Joe Siletto, Managing Partner at J.P. Morgan Life Sciences Private Capital, emphasized the potential of magnetic technology to address complications that have remained a challenge in minimally invasive surgery.
“The use of magnets in surgery is a game-changing technology to address serious adverse events, such as leaks and bleeding, which have troubled surgeons since the advent of minimally invasive surgery over 50 years ago,” Siletto said.
He also highlighted the role of GT Metabolic co-founder and Chief Medical Officer Dr. Michel Gagner in advancing the company’s technology.
According to Siletto, Gagner has spent the past 20 years pursuing the use of magnets as a means of improving anastomosis creation and providing surgeons with an alternative to conventional approaches. His work has focused on reducing surgical complications and improving patient outcomes through the development of new techniques for joining tissue.
The investment reflects J.P. Morgan Life Sciences Private Capital’s confidence in GT Metabolic’s technology and its potential to expand across additional surgical applications. The partnership is expected to provide the company with capital to support its next phase of development, including commercial expansion and further investment in its product portfolio.
Funding to Support Product Development and Surgeon Training
Thierry Thaure, co-founder and Chief Executive Officer of GT Metabolic, said the financing would help the company accelerate its development and commercialization plans.
“J.P. Morgan Life Sciences Private Capital’s growth investment will help accelerate both product development, surgeon trainings and worldwide commercial expansion,” Thaure said.
He described the financing as an important milestone for the company as it works to advance additional anastomotic products and deliver improved care for patients.
The funding is expected to support several areas of the business. These include continued product development, the expansion of surgeon education and training initiatives, and the company’s efforts to increase the availability of its technology in international markets.
Surgeon training is an important consideration for the introduction of new surgical devices. Healthcare professionals must understand how a device works, how it should be incorporated into existing procedures, and what clinical and operational factors need to be considered when using it. By investing in training, GT Metabolic aims to support appropriate product use and facilitate adoption among surgical teams.
The company also plans to expand its presence in additional surgical settings, with endoscopic and colorectal procedures among its next priorities. These applications could broaden the range of clinical situations in which magnetic compression technology may be used, subject to the necessary development work and regulatory requirements.
Further expansion into additional indications is expected as GT Metabolic continues to develop its product portfolio and assess opportunities across gastrointestinal surgery.
Expanding International Commercial Reach
GT Metabolic’s technology has received authorizations for anastomosis in several surgical procedures across the United States, Europe, South America, and other regions. These regulatory milestones provide a foundation for the company’s commercial expansion, although specific product indications and permitted uses may vary by jurisdiction.
Anthony Perry, Vice President at J.P. Morgan Life Sciences Private Capital, said the investment would help GT Metabolic advance its efforts to transform minimally invasive surgical care.
“We are proud to partner with GT Metabolic as it works to transform minimally invasive surgical care,” Perry said.
He added that the investment would support the company’s commercialization activities, continued development of additional anastomosis indications, including colorectal surgery, and efforts to expand access for patients and healthcare providers.
International expansion will be an important component of GT Metabolic’s strategy as it works to introduce its technology to more surgical centers. Commercial growth in different healthcare markets requires coordination among regulatory, clinical, training, and distribution activities. The new capital is expected to help the company strengthen these capabilities as it progresses toward broader market adoption.
The investment also provides an opportunity for GT Metabolic to continue developing its relationships with healthcare professionals and institutions interested in alternatives to conventional anastomotic techniques.
First Institutional Financing Partnership
The Series C investment marks GT Metabolic’s first institutional financing partnership and represents the fifth investment made by the J.P. Morgan Life Sciences Private Capital team.
The partnership underscores J.P. Morgan’s strategy of supporting founders and founder-owned businesses through the provision of growth capital and strategic resources. For companies developing medical technologies, such support can be important in moving from product development and regulatory authorization toward broader commercialization.
Medical device companies often face substantial requirements as they expand into new markets, including manufacturing, regulatory compliance, clinician education, and continued product development. Access to growth financing can help address these requirements and support the infrastructure needed to serve additional healthcare providers.
For GT Metabolic, the investment comes as the company seeks to build on its regulatory achievements and expand the clinical applications of its magnetic anastomosis system.
The Series C investment positions GT Metabolic to pursue its next stage of growth, with a focus on commercial expansion, product innovation, and the development of additional surgical indications.
The company’s linear magnetic anastomosis technology is designed to offer surgeons an alternative to conventional sutures and staples by using magnetic compression to facilitate tissue connections. Its compatibility with endoscopic, robotic, and laparoscopic surgical approaches could also support its use across different procedural settings.
With J.P. Morgan Life Sciences Private Capital providing financial support, GT Metabolic plans to accelerate surgeon training, strengthen its global commercial operations, and expand into areas such as colorectal surgery.
The company’s longer-term opportunity will depend on its ability to demonstrate the value of its technology in clinical practice, secure the necessary authorizations for additional indications, and establish adoption among surgeons and healthcare institutions.
As the medical technology sector continues to explore methods for improving minimally invasive procedures, GT Metabolic is seeking to address a longstanding challenge in gastrointestinal surgery: creating reliable tissue connections while supporting healing and reducing the risk of serious complications.
The new financing provides the company with additional resources to advance that objective and expand the availability of its magnetic anastomosis technology across global markets.
About GT Metabolic Solutions Inc.
GT Metabolic Solutions is a medical device company that develops and manufactures magnetic compression products designed for the safer creation of gastrointestinal anastomoses. With locations in Minneapolis, Minnesota, San Jose, California, and Montréal, Canada, GT Metabolic’s products have demonstrated efficacy in reliably creating anastomoses while driving low complication rates to reduce the need for surgical re-interventions. For more information, visit https://gtmetabolic.com/.
About J.P. Morgan Life Sciences Private Capital
J.P. Morgan Life Sciences Private Capital is the life sciences platform of J.P. Morgan Private Capital that partners with leading early-stage biotherapeutics and late-stage healthcare companies. The early stage biotechnology practice is focused on company creation, Seed and Series A investments across all therapeutic areas in biotechnology.
The late-stage healthcare practice is focused on commercial-stage medical devices, pharmaceutical and device services, biopharma, and tools and diagnostics companies. J.P. Morgan Asset Management is a global leader in alternatives, with over 60 years of experience managing alternative investments, and $460 billion in assets under supervision spanning real estate, private equity, private credit, liquid alternative products, infrastructure, transport, hedge funds, and forestry.